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ABSTRACT
FOXO1 DIFFERENTIALLY REGULATES
BOTH NORMAL AND DIABETIC GINGIVAL WOUND HEALING
Hyeran Helen Jeon
Dana T. Graves

We have previously demonstrated that keratinocyte-specific forkhead box O1 (FOXO1)
deletion interferes with keratinocyte migration in normal skin wounds. However it has an
opposite effect in diabetic skin wounds, significantly improving the healing response. In
addition we found that skin epithelium regulates connective tissue healing mediated by
FOXO1, which is strongly associated with wound angiogenesis in our microarray results.
However, a role for keratinocytes in this complex process has yet to be investigated. To
this end, we investigated possible involvement of gingival keratinocytes in connective
tissue healing under both normal and diabetic conditions. We found that keratinocytespecific FOXO1 deletion interfered with normal gingival connective tissue healing by
decreasing granulation tissue formation and angiogenesis, which were mediated by
vascular endothelial growth factor A (VEGF-A). In particular this is the first evidence that
avascular epithelium regulates angiogenesis involving the VEGF-A secretion mediated
by FOXO1. Furthermore, we investigated the possible role of epithelial to mesenchymal
transition (EMT) during wound healing using the lineage tracing in transgenic mice. But
we did not find any keratinocyte-specific reporter activity in the connective tissue
indicating that there was no apparent trans-differentiation of keratinocytes into typical
fibroblasts or myofibroblasts during wound healing. These results establish an important
role of epithelial cells in accelerating wound angiogenesis and connective tissue healing
through a FOXO1-dependent mechanism.
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CHAPTER 1
INTRODUCTION

1.1 Wound Healing, Diabetes and Angiogenesis
Wound healing is a dynamic interactive process that begins at the moment of wounding
and involves soluble mediators, many cell types, and extracellular matrices (5-7). The
healing of oral wounds proceeds through similar stages as that of skin wounds including
three phases: 1) inflammatory phase, 2) proliferative phase, and 3) maturation phase
(8). A number of cell subsets contribute to healing, including keratinocytes, fibroblasts,
endothelial cells and inflammatory cells. The activity of these cells is regulated by
cytokines acting in both autocrine and paracrine fashion to bring about efficient healing
(9). The goal of the inflammatory phase is to obtain hemostasis and to provide an influx
of neutrophils and macrophages into the wound bed in a milieu of cytokines and growth
factors. At the end of the inflammatory phase apoptosis of inflammatory cells appears
concurrently with re-epithelialization of the wound and may be a signal of healing at that
site in the wound (10). The second phase, the proliferative phase, is characterized by
the granulation tissue formation, angiogenesis, deposition of new extracellular matrix
(ECM), and re-epithelialization. Although granulation is classically assigned to the
proliferative stage, angiogenesis is initiated immediately upon wounding and is mediated
throughout the entire wound healing process. In order to manufacture the extracellular
matrix fibroblasts require oxygen and nutrients so there is a requirement for
angiogenesis (11). The third phase, the maturation phase, involves wound contraction
and remodeling. Collagen is realigned along tension lines and cells that are no longer
needed are removed by programmed cell death or apoptosis.
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Diabetes has a major effect on wound healing. It is a chronic disease characterized by
elevated blood sugar levels resulting from either lack of insulin production or resistance
to insulin (12). It is one of the most challenging health problems of the 21st century.
Some 382 million people worldwide (8.3% of adults) are estimated to have diabetes (13).
If these trends continue, by 2035, some 592 million people, or one adult in 10, will have
diabetes. The largest increases will take place in the regions where developing
economies are predominant. In addition, diabetes imposes a large economic burden on
individuals and families, national health systems, and countries. Health spending on
diabetes accounted for 10.8% of total health expenditure worldwide in 2013. There are
numbers of complications caused by diabetes, including increased heart disease, stroke,
blindness, kidney failure, and delayed wound healing (14). Diabetes affects the oral
cavity by increasing the prevalence of caries, gingivitis, periodontal disease, implantitis,
fibromas, and traumatic ulcers (15). A number of factors may contribute to impaired
healing in diabetics, such as decreased or impaired growth factor production (16-18),
angiogenic response (18, 19), macrophage function (20), collagen accumulation,
epidermal barrier function, quantity of granulation tissue (18), keratinocyte and fibroblast
migration and proliferation, number of epidermal nerves (21), bone healing, and balance
between the accumulation of ECM components and their remodeling by matrix
metalloproteinases (MMPs) (22) (Fig. 1). One of the major cellular components of wound
granulation tissue relevant to healing and angiogenesis is macrophages (23, 24). Wound
macrophages have been established as key players in the maintenance of tissue
homeostasis through tissue remodeling and repair via the release of mediators at the
wound site (25). In support of this view, suppressed recruitment of macrophages into
granulation tissue impairs wound healing (26, 27). Decreased numbers of macrophages
and insufficient macrophage activation contribute to the impaired healing of diabetic
2	
  	
  
	
  

wounds (20). Increased fibroblast apoptosis has been proposed to be a mechanism for
diabetes-impaired

dermal

wound

healing

(28-30).

Patients

with

diabetes

are

characterized by a reduction in angiogenesis, which is an important part of the
proliferative phase of healing. Limited penetration of new blood vessels into the wound
would restrict entry of inflammatory cells, and high amounts of distinct angiogenic factors

	
  
Figure 1. Mechanisms of wound healing in healthy people versus people with diabetes (31)
In healthy individuals (left), the acute wound healing process is guided through multiple signals
released by keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets. During
wound-induced hypoxia, VEGF released by keratinocytes, macrophages and fibroblasts induces
the phosphorylation and activation of Endothelial Nitric Oxide Synthase (eNOS) in the bone
marrow, resulting in an increase in NO levels, which triggers the mobilization of bone marrow
EPCs to the circulation. On the contrary, in people with diabetes (right) keratinocytes show less
migration and incomplete differentiation. Fibroblasts demonstrate the decreased migration and
proliferation. Also, the amount of VEGF released by several different cell types is reduced,
resulting in impaired eNOS activation in bone marrow, which directly limits endothelial progenitor
cells (EPC) homing. Therefore it impairs wound healing.
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produced by immune cells are limited (32). Factors that play a decisive role in diabetesassociated wound healing disorders comprise augmented inflammatory responses,
impaired granulation tissue formation, reduced growth factors and a disturbed
angiogenesis (13). In particular, hyperglycemia-related microvascular pathology is
thought to be a critical contributor to impaired diabetic healing (33). Hyperglycemia can
affect endothelial function via several major mechanisms, including toxic effects on
endothelial cells via nitric oxide, oxidative stress and inflammation (34, 35), and
accumulation of advanced glycation end products (AGEs) that results in altered
extracellular matrix and disrupted angiogenic growth factor signaling (36, 37). In vitro
studies in high glucose culture conditions demonstrated increased endothelial apoptosis
(38, 39); impaired proliferation, adhesion, and tube formation (40, 41); and changes in
cytokine production (16).
Streptozotocin (STZ) is most widely used to induce experimental diabetes in rodents
because of its simplicity and reproducibility (42). STZ (2-deoxy-2-(3-methyl-3nitrosourea)-1-D-glucopyranose) is a broad-spectrum antibiotic which is produced by
Streptomyces achromogenes. The diabetogenic effect of STZ was first reported in 1963
by Rakieten et al. after injection of a single intravenous dose in rats and dogs (43). STZ
is similar enough to glucose (Glu) and N-acetyl glucosamine (GlcNAc) (Fig. 2) to be
transported into the pancreatic β cells by the glucose transport protein GLUT2, but is not
recognized by the other glucose transporters. This explains its relative toxicity to β cells,
since these cells have relatively high levels of GLUT2 (44, 45). Once it is taken it causes
β-cell death by DNA fragmentation due to the nitrosourea moiety. Three major pathways
associated with cell death are: (i) methylation of DNA by the formation of carbonium ion
(CH3+) resulting in the activation of the nuclear enzyme poly ADP-ribose synthetase as
part of the cell repair mechanism and therefore NAD+ depletion; (ii) free radical
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generation as hydrogen peroxide and (iii) nitric oxide production (46, 47). The toxic
effects of STZ are not restricted to pancreatic β-cells. STZ also causes renal, cardiac
and adipose tissue damage and increases oxidative stress, inflammation and endothelial
dysfunction (48). Moreover, several studies have described immune-modifying effects of
STZ both in vitro and in vivo (49-51).

A

B
	
  

C
	
  

	
  

Figure 2. Chemical structures of (A) glucose, (B) N-acetyl glucosamine and (C) streptozotocin

Wound angiogenesis is critical to wound healing. Angiogenesis is initiated upon
wounding by multiple molecular signals, including hemostatic factors, inflammation,
cytokine growth factors, and cell-matrix interactions. Initially, there is no vascular supply
to the wound center and the appearance of new viable tissue is limited to wound
margins that are in contact with uninjured tissue through direct contact with uninjured
blood vessels and through the process of short-distance diffusion through the uninjured
interstitium. Under normal conditions, a tissue or tumor cannot grow beyond 1 to 2 mm
in diameter without neovascularization. This distance is defined by limits in the diffusion
of oxygen and metabolites, such as glucose and amino acids (52). The vascular
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component depends upon angiogenesis, in which new vessels appear as early as d 3
after wounding (53). The formation of new blood vessels in the developing acute
granulation tissue (angiogenesis) occurs by a budding or sprouting mechanism from
intact vessels at the wound borders. The development of vascular outgrowths requires
endothelial cell proliferation. Numerous tissue growth factors such as vascular
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) play central
regulatory roles in neovascularization and subsequent tissue repair (54). Macrophages
also appear to be necessary for wound neovascularization to occur, especially along
wounded tissue oxygen gradients (55). As collagen accumulates in the granulation
tissue to produce scar, the density of blood vessels diminishes (56). New capillaries
proliferate via a cascade of biological events to form granulation tissue in the wound
bed. Injured tissue releases growth factors that bind to their receptors on endothelial
cells, activating signal transduction pathways and stimulating endothelial proliferation,
migration, and vascular tube formation. Bone marrow derived endothelial progenitor cells
are mobilized and become incorporated into new blood vessels. Stabilization of the
vasculature occurs through the recruitment of smooth muscle cells and pericytes (Fig.
3). Several evidences implicate VEGF as a significant factor in wound healing
immediately after injury (53, 57). Maximal activity occurs during a period approximately 3
to 7 d after injury. Once the wound is granulated, angiogenesis ceases and blood
vessels decline as endothelial cells undergo apoptosis.
Defects in the angiogenesis delay healing and these are evident in chronic wounds. In
general, the process of angiogenesis is believed to be controlled by changes in the
levels

of

proangiogenic

microenvironment

and

surrounding

antiangiogenic
the

vasculature

molecules
(1).

Many

present

within

the

proangiogenic

and

antiangiogenic mediators have been identified (Table 1). Vascular endothelial growth
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Figure 3. The Angiogenesis Cascade of Events and Multiple targets Injured tissues release
growth factors that bind to their receptors on endothelial cells, activating signal transduction
pathways and stimulating endothelial proliferation, migration, and vascular tube formation. Bone
marrow derived endothelial stem cells are mobilized and become incorporated into new blood
vessels. Stabilization of the vasculature occurs through the recruitment of smooth muscle cells
and pericytes.
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Table 1. Molecular Regulators of Angiogenesis (Source: The Angiogenesis Foundation)
Angiogenic Stimulators
Angiogenin
Angiopoietin-1
Del-1
Fibroblast growth factors: acidic (aFGF) and
basic (bFGF)
Follistatin
Granulocyte colony-stimulating factor (GCSF)
Hepatocyte growth factor (HGF) /scatter
factor (SF)
Interleukin-8 (IL-8)
Leptin
Midkine
Placental growth factor

Platelet-derived endothelial cell growth
factor (PD-ECGF)
Platelet-derived growth factor-BB (PDGFBB)
Pleiotrophin (PTN)
Progranulin
Proliferin
Transforming growth factor-alpha (TGFalpha)
Transforming growth factor-beta (TGF-beta)
Tumor necrosis factor-alpha (TNF-alpha)
Vascular endothelial growth factor
(VEGF)/vascular permeability factor (VPF)

Angiogenesis Inhibitors
Angioarrestin
Angiostatin (plasminogen fragment)
Antiangiogenic antithrombin III
Arrestin
Chondromodulin
Canstatin
Cartilage-derived inhibitor (CDI)
CD59 complement fragment
Endostatin (collagen XVIII fragment)
Endorepellin
Fibronectin fragment
Fibronectin fragment (Anastellin)
Gro-beta
Heparinases
Heparin hexasaccharide fragment
Human chorionic gonadotropin (hCG)
Interferon alphagamma
Interferon inducible protein (IP-10)
Interleukin-12
Kringle 5 (plasminogen fragment)

Metalloproteinase inhibitors (TIMPs)
2-Methoxyestradiol
PEX
Pigment epithelium derived factor (PEDF)
Placental ribonuclease inhibitor
Plasminogen activator inhibitor
Platelet factor-4 (PF4)
Prolactin 16kD fragment
Proliferin-related protein (PRP)
Prothrombin kringle 2
Retinoids
Soluble Fms-like tyrosine kinase-1 (S-Flt-1)
Targeting fibronectin-binding integrins
Tetrahydrocortisol-S
Thrombospondin-1 (TSP-1) and -2
Transforming growth factor-beta (TGF-b)
Troponin I
Tumstatin
Vasculostatin
Vasostatin (calreticulin fragment)

8	
  	
  
	
  

factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived growth factor and
placental growth factor (PlGF) are proteins that stimulate angiogenesis whereas
angiostatin (a fragment of plasminogen), endostatin (a fragment of collagen XVIII) and
thrombospondin-1 are examples of angiogenesis inhibitors. The maintenance of vessels
in a quiescent state is thought to occur when the level of antiangiogenic signals outweigh
proangiogenic signals; however, periods of active angiogenesis occur when endothelial
cells sense a shift in the balance of these mediators, with proangiogenic signals
predominating over antiangiogenic signals. The angiogenic switch concept was
proposed by Folkman and Hanahan, who first used it to describe the regulation of tumor
angiogenesis (58). These events are stimulated in part by a number of mitogens and
chemotactic factors. The soluble factors shown to be mitogenic for endothelial cells in
vitro and angiogenic in vivo include different members of the fibroblast growth factor
family, transforming growth factor-α (TGF-α), epidermal growth factor (EGF) (5) and
platelet-derived growth factor BB (6). Furthermore, transforming growth factor-β (TGF-β)
and tumor necrosis factor-α (TNF-α) have been shown to be angiogenic in vivo, although
they inhibit endothelial cell growth in vitro (7-11). Thus, they may be indirectly angiogenic
under certain conditions. The vascular endothelial growth factor (VEGF) is the most
potent and specific vascular growth factor. VEGF family comprises in mammals five
members: VEGF-A, placental growth factor (PIGF), VEGF-B, VEGF-C and VEGF-D. The
latter ones were discovered later than VEGF-A and, before their discovery, VEGF-A was
termed VEGF. It is a soluble protein secreted by a wide variety of cell types. The
inhibition of VEGF by antibody has been shown to inhibit angiogenesis (59-61). VEGF-A
levels are regulated through transcriptional control and mRNA stability (62). Four
different human isoforms of VEGF-A including VEGF-A121, VEGF-A165, VEGF-A189, and
VEGF-A206, have been isolated from various sources and arise by alternative splicing of
9	
  	
  
	
  

mRNA (12). The most abundant isoform found in human tissue is VEGF-A165. Whereas
all VEGF-A isoforms seem to have similar biological activities, only VEGF-A121 and
VEGF-A165 are secreted in soluble form, whereas the higher-molecular-weight forms
apparently remain cell associated (63). VEGF-A plays a pivotal role during the
angiogenic response in tissue repair by regulating vascular permeability, the influx of
inflammatory cells into the site of injury, migration and proliferation of pre-existing
endothelial cells and the recruitment of marrow-derived endothelial progenitor cells to
the local wound site (4, 19, 57, 64, 65). In skin major sources of VEGF-A are epidermal
keratinocytes, macrophages, endothelial cells, fibroblasts and mast cells (1, 66-68).
VEGF-A is up-regulated during the early days of healing, when capillary growth is
maximal. Delayed wound closure and reduced vessel density have been reported in
mice lacking VEGF-A in keratinocytes (65).
Brown et al. demonstrated expression of VEGF
mRNA in proliferating keratinocytes of the newly
formed epithelium during wound healing (4) (Fig.
4). In contrast, expression of one of the receptors
for VEGF-A (flt-1) was found to be up-regulated
Figure 4. In situ expression of VEGF
mRNA in healing rat. Epidermal
labeling was maximal on days 2-3 (4).

in the sprouting blood vessels at the wound edge
(19) and in endothelial cells of the granulation

tissue (20). These findings suggest that keratinocyte-derived VEGF-A stimulates
angiogenesis during wound healing in a paracrine manner. Detmar et al. characterized
the effects of several cytokines and growth factors on the expression and secretion of
vascular permeability factor (VPF)/VEGF mRNA and protein by cultured human
epidermal keratinocytes, as well as the effect of VPF/VEGF on the growth of cultured
human dermal microvascular endothelial cells (69). These results suggest that the
10	
  
	
  
	
  

avascular

epidermis

has

the

capacity

to

regulate

dermal

angiogenesis

and

microvascular permeability by a paracrine mechanism involving the secretion of
VPF/VEGF.
VEGF-A transcription and secretion are elevated in partial (4) and full-thickness skin
wounds (70, 71). In partial thickness wounds, keratinocytes at the wound edge express
elevated VEGF-A as early as 1 d after injury and eventually migrate to cover the defect.
Epidermal labeling for VEGF-A mRNA reaches a peak after 2–3 d, coincident with a
peak in vascular permeability, and levels remain elevated until epidermal coverage is
complete. Similarly maximal VEGF-A mRNA is found between 3 and 7 d after fullthickness wounding during the period of granulation tissue formation (70). The time
course of VEGF-A expression provides insight into the progression of wound healing.
During the proliferative phase of repair occurring approximately 3 to 7 d post-wounding
capillary growth and differentiation are at a maximum. During this period, VEGF-A is upregulated to promote the early stages of angiogenesis (i.e., vascular dilation,
permeability, migration, and proliferation) (57). Antibody neutralization of VEGF-A
diminishes the chemotactic and angiogenic properties of wound fluid, thus revealing
further evidence for the importance of VEGF-A in wound repair (57). Additionally,
wounds of streptozotocin-induced diabetic mice demonstrate diminished synthesis of
several growth factors including VEGF-A (71).
To date, the majority of the effects of VEGF-A during wound repair have been attributed
to its proangiogenic activity (1) (Fig. 5); however, recent studies have indicated that in
addition to vascular endothelial cells, other cells such as keratinocytes and
macrophages express VEGFRs and can respond directly to VEGF-A. VEGF-A likely
promotes collagen deposition and epithelialization as well (53). Traditionally, VEGF-A
produced by epidermal keratinocytes was thought to act in a paracrine manner,
11	
  
	
  
	
  

stimulating endothelial cells within the granulation tissue. However, functional VEGFRs
have been recently identified on keratinocytes (72-75), which suggests the possibility of
autocrine VEGF-A signaling in keratinocytes as well as direct effects of VEGF-A derived
from other cellular sources on keratinocytes. Direct effects of VEGF-A on keratinocytes
have been described in vitro using cultured primary human keratinocytes (72) and
primary mouse keratinocytes (73). Those studies suggested possible roles for VEGF-A
in the regulation of keratinocyte proliferation, migration and survival (72, 73, 75-77). In
addition to keratinocytes, myeloid cells (monocytes and macrophages) are another
important cell type known to respond to VEGF-A during wound healing (1). Monocytes
and macrophages express VEGFR-1 and VEGF-A has been shown to increase the
migration of these cells in vitro through VEGFR-1 (78-80). A higher density of
macrophages has been reported in wounds from VEGF-A transgenic mice (81).

Figure 4
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Figure 5. Cellular sources and actions of VEGF during wound healing (1)
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1.2 Epithelial-Mesenchymal Transition (EMT) in Wound Healing

Epithelial to mesenchymal transition (EMT), originally identified as an essential
differentiation and/or morphogenetic process during embryogenesis, may contribute to
wound healing, tissue remodeling, fibrosis, and metastatic malignancies (82). Elizabeth
Hay first described an “epithelial-mesenchymal transformation” using a model of chick
primitive streak formation (83). In the intervening time, the term “transformation” has
been replaced with “transition,” reflecting in part the reversibility of the process and the
fact that it is distinct from neoplastic transformation (84). Three distinct manifestations of
EMT have been proposed based on stages of development and associated biomarkers;
1) embryogenesis and organ development (Type I), 2) wound healing and organ fibrosis
in mature tissue (Type II), and 3) tumorigenesis and cancer metastasis (Type III) (Fig. 6).
EMT is a trans-differentiation process by which epithelial cells lose their epithelial
characteristics and acquire a mesenchymal phenotype and is characterized by changes
in cell morphology, and disruption of tight junctions and adherent junctions (85) (Fig. 7).
Down-regulation of E-cadherin is considered a key step in EMT (Fig. 8). A growing
number of transcriptional molecules have been found to be involved in the EMT process
(Table 2) (86). Among them, ectopic expression of Snail has been reported to suppress
E-cadherin expression, leading to a full EMT phenotype, whereas silencing of Snail
expression reverses this process (87). The acquired mesenchymal phenotype is
characterized by expression of cytoskeletal proteins such as α-smooth muscle actin (αSMA) and vimentin, as well as matrix metalloproteinases (MMPs). As a result of these
phenotypic changes, epithelial cells are released from the surrounding tissue and
become migratory and invasive.
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Figure 6. Different types of Epithelial to mesenchymal transition (88); (A) embryogenesis
and organ development (Type I), (B) wound healing and organ fibrosis in mature tissue (Type II),
and (C) tumorigenesis and cancer metastasis (Type III)

Figure 7. Epithelial to mesenchymal transition (EMT) (88). An EMT involves a functional
transition of polarized epithelial cells into mobile and ECM component-secreting mesenchymal
cells.
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Rac1b

MMPs

Hypoxia

p190
Rho
GAP

Rac1

RhoA

Cdc42

Filopodia
Lamellipodia
Migration
Invasion

of skin wounds: keratinocyte-driven re-epithelialization Basement membrane degradati

and fibroblast-mediated contraction of the newly formed connective tissue bed beneath
the wound site, pulling the edges of the wound closer together (92). During reepithelialization, migrating keratinocytes undergo numerous phenotypic and functional
alterations reminiscent of epithelial–mesenchymal transformation, including disruption of
desmosomes and hemidesmosomes, alterations in the actin-based cytoskeleton,
retraction of intermediate filaments and loss of cell polarity. Epithelial cells migrate from
the	
   edges of the wound very soon after the initial insult until a complete sheet of cells
covers the wound and attaches to the matrix below. In wounds that are primarily closed,
this phase can be completed within 24 hours. Changes in cytokine concentration result
in epithelial cells switching from a motile phenotype to a proliferative one in order to
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Table 2. Epithelial to Mesenchymal Transition Markers (86)
Proteins that increase in abundance	
  
N-cadherin

FOXC2

Vimentin

Sox10

Fibronectin

MMP-2

Snail1 (Snail)

MMP-3

Snail2 (Slug)

MMP-9

Twist

Integrin αvβ6

Goosecoid

Proteins that decrease in abundance
E-cadherin

Cytokeratin

Desmoplakin

Occludin

Proteins whose activity increases
ILK

Rho

GSK-3β

Proteins that accumulate in the nucleus
β-catenin

Snail1 (Snail)

Smad-2/3

Snail2 (Slug)

NF-κβ

Twist

In vitro functional markers
Increased migration

Elongation of cell shape

Increased invasion

Resistance to anoikis

Increased scattering
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repopulate epithelial cell levels and complete wound repair (93). In wounds that heal by
secondary intention, the area lacking epithelial cells can be large and the wound must
contract significantly before epithelialization can be completed. Wound contraction
process is performed by myofibroblasts activated by TGF-β (70). The sources of
myofibroblasts in a healing wound are numerous. Emerging evidence suggests that
epithelial cells are also an important source of myofibroblasts in fibrosis and cancer (94).
But, its role during wound healing is ambiguous. Several studies have examined Slug
expression in skin injury models to provide evidence for an EMT-like process in
cutaneous wound healing (95, 96). Savagner et al. analyzed the expression of Snai2
during the wound healing by in situ hybridization. Snai2 expression was elevated in
keratinocytes bordering cutaneous wounds in mice in vivo, in keratinocytes migrating
from mouse skin explants ex vivo, and in human keratinocytes at wound margins in vitro.
Overexpression of Snai2 in keratinocytes caused increased cell spreading and
desmosomal disruption in vivo and accelerated in vitro wound healing, suggesting a
critical role for Snai2 in epithelial keratinocyte migration and wound healing.
Furthermore, in Slug-null mice, a 1.7-fold decrease in re-epithelialization was seen in an
excisional wound model. These studies indicate that an EMT-like process might occur in
the re-epithelialization process of wound healing.
To date, several studies supporting EMT during wound healing have focused on reepithelialization

through

keratinocyte

migration.

On

the

other

hand,

studies

demonstrating EMT trans-differentiation from keratinocytes into myofibroblasts during
wound healing are rare. Yan et al. characterized the EMT-like features in acute and
fibrotic wounds in human skin (89). In tissue staining, they rarely noticed the colocalization of both E-cadherin and vimentin/fibroblast-specific protein 1 (FSP-1) cells in
epithelial layers. This is understandable because gain of mesenchymal and loss of
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epithelial markers occurs simultaneously, leaving very little window to trap the transition
process. However, such dynamic transition has been recapitulated in vitro. With colocalization stain method they did not observe trans-differentiation of human
keratinocytes into myofibroblasts. Trans-differentiation is ideally demonstrated by
lineage tracing using transgenic mice in which epithelial cells have been “permanently”
marked.
Among the major proteins exclusive to epithelial tissues are keratins, a family of >20
proteins whose members are differentially expressed in a tissue-, differentiation-, and
developmental- specific fashion (97). Based on sequence homologies, these proteins
can be subdivided into two distinct groups: type I keratins are smaller (40-56.5 kDa) and
acidic (pKi = 4.5-5.5), and type II keratins are larger (53-67 kDa) and more basic (pKi =
5.5-7.5) (98). Type I and type II keratins are expressed as specific pairs. Keratin 14 (K14)
and its partner K5 are the major proteins expressed by the mitotically active cells of the
epidermis and its appendages (99, 100) and the genes encoding these keratins are
abundantly transcribed in cultured human keratinocytes (101). For these reasons, the
K14 and K5 promoters are especially attractive candidates for use in studies of
keratinocytes. For our study we utilized the Cre-loxP recombination system for the
introduction of a spatiotemporal gene ablation with human keratin 14 (K14) promoter.
The system generally requires cross mating of two lines of genetically manipulated mice
(Fig. 9). One line of mice carries alleles with a gene of interest flanked by two identically
orientated loxP sites. The other line contains a Cre transgene in which the expression of
Cre is controlled by a defined promoter. Recombination between the two loxP sites in
the mated mice results in the catalysis of a deletion of the region flanked by the loxP
sites; this is dependent on Cre transgene expression.
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Figure 9. Cre-loxP recombination system

To study EMT we examined transgenic mice expressing Cre and a fusion protein
between Cre recombinase and the tamoxifen responsive hormone-binding domain of the
estrogen receptor (CreER). Expression of the fusion protein was under the control of the
human keratin 14 (K14) promoter. The CreER recombinases are inactive, but can be
activated by the synthetic estrogen receptor ligand 4-hydroxytamoxifen (OHT), therefore
allowing for external temporal control of Cre activity. By combining tissue-specific
expression of a CreER recombinase with its tamoxifen-dependent activity, the excision
of floxed chromosomal DNA can be controlled in a time- and tissue-specific manner. In
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order to label the fluorescence to keratinocyte, we crossed K14CreER transgenic mice
with

ROSA26

TdTomato

is

Cre

reporter

expressed

mouse

following

(B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J).

Cre-mediated

recombination

with

tamoxifen

administration. To our knowledge, this model is the first to assess the role of EMT as the
mechanism of trans-differentiation of keratinocytes into typical myofibroblasts during
wound healing.
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1.3 FOXO1, Wound healing and Angiogenesis

The forkhead boxO (FOXO) transcription factors represent a subclass of a large family
of forkhead proteins characterized by the presence of a winged-helix DNA binding
domain called Forkhead box (102). In mammals this subclass comprises four members:
FOXO1 (or FKHR), FOXO3 (or FKHRL1), FOXO4 (also called AFX) and FOXO6 (103).
The four mammalian isoforms may have both distinct and overlapping functions and
compensation of one member by another may mask the function of individual FOXOs.
FOXO1, 3 and 4 are ubiquitously expressed and relatively abundant in bone and bone
cells. FOXO6 expression is confined to the brain (104). FOXOs are master signaling
integrators that translate environmental stimuli, like hormonal changes, inflammation,
and oxidative stress, into dynamic gene expression programs involved in many
physiological and pathological processes (Fig. 10). Among the many biological functions
they serve, FOXO proteins are known best for three defining properties: survival, by
means of resistance to oxidative stress; glucose metabolism, a property specific to
FOXO1; and suppression of tumorigenesis, a property also mainly regulated by FOXO1
(105). Balancing the multiple avenues of FOXO activity are several opposing signaling
pathways that regulate their localization to the nucleus, where they are active (106-108).
Among them FOXO1 is particularly noteworthy in that it regulates the most diverse array
of the FOXO’s known biological activities, including organ growth, insulin action,
tumorigenesis, and angiogenesis. It is a main target of insulin signaling and regulates
metabolic homeostasis and organismal survival at many different levels.
FOXO proteins are deactivated by the insulin/PI3K/Akt signaling pathway (2). A major
form of regulation is Akt-mediated phosphorylation of FOXO in response to insulin or
growth factors. Phosphorylation at three conserved residues results in the export of
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Figure 10. In the absence of insulin or growth factors, FOXO transcription
factors are located in the nucleus, where they specify target gene expression
(2).

FOXO factors from the nucleus to the cytoplasm, thereby inhibiting FOXO-dependent
transcription. FOXO proteins are also phosphorylated by other protein kinases, including
JNK or the mammalian ortholog of the St20-like protein kinase (Mst1), which
phosphorylate FOXO under conditions of oxidative stress. This phosphorylation leads to
translocation of FOXO into the nucleus, thus opposing Akt’s action. In addition to being
post-translationally modified by phosphorylation, FOXO proteins also bind to co-activator
or co-repressor complexes and become acetylated or deacetylated.
Recent evidences indicate that FOXO1 plays a critical role in wound healing. Mori et al.
performed immunohistochemistry (IHC) analysis to determine which cells express
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FOXO1 protein during skin wound healing (109). By only 1 day after injury, FOXO1 was
markedly present in the leading edge and basal layer of keratinocytes and hair follicles
and in recruited neutrophils. Seven days after injury FOXO1 was present in
macrophages, fibroblasts and endothelial cells at the wound site. Ponugoti et al.
demonstrated that FOXO1 promotes wound healing through the up-regulation of TGF-β1
and prevention of oxidative stress in normal wounds (110). Lineage-specific FOXO1
deletion in keratinocytes interfered with wound healing and keratinocyte migration in
normal skin and mucosal wounds (110-113). Surprisingly, the same deletion of FOXO1
in diabetic wounds had the opposite effect, significantly improving the healing response
(111-113). In high glucose, FOXO1 enhanced expression of serpin peptidase inhibitor,
clade B (ovalbumin), member 2 (SERPINB2), and chemokine (C-C motif) ligand 20
(CCL20). The impact of high glucose on keratinocyte migration was rescued by silencing
FOXO1, by reducing SERPINB2 or CCL20, or by insulin treatment (111). Thus, FOXO1
expression can positively or negatively modulate keratinocyte migration and wound
healing by its differential effect on downstream targets modulated by factors present in
diabetic but not normoglycemic healing. In addition FOXO1 expression in vascular cells
is necessary for vascular cell development as well as for the biological response to
cellular mediators. Mice homozygous for a Foxo1–/– allele, but not Foxo3a–/– or Foxo4–/–
mice, die during embryogenesis from defects in vascular development (16, 17).
Endothelial cell colonies in Foxo1-deficient mice fail to respond to vascular endothelial
growth factor in a manner similar to wild-type endothelial cells (114). Although these
studies suggest an essential role of FOXO1 in the formation and maturation of the
nascent vasculature, relatively little is known about the function and significance of the
distinct FOXO family members for the angiogenic activity of endothelial cells and
postnatal vessel formation (115). In addition our microarray results show that those
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genes selectively decreased by FOXO1 knockdown in normal human epidermal
keratinocytes (NHEK) are most strongly associated with angiogenesis, suggesting that
FOXO1 activation in keratinocytes may have a strong relationship with wound
angiogenesis (Table 3).

Table 3. Genes down-regulated by FOXO1 knockdown and related to angiogenesis

Gene name

Fold change by FOXO1 knockdown

Interleukin 18

-1.91197

Vascular endothelial growth factor C

-1.82767

Angiopoietin-like 4

-1.63326

Vascular endothelial growth factor A

-1.61825

Cysteine-rich, angiogenic inducer, 61

-1.53097

Connective tissue growth factor

-1.49486

Hypoxia inducible factor 1, alpha subunit

-1.38889

Fibroblast growth factor 2 (basic)

-1.35659
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1.4 Hypothesis

Diabetes is a significant health concern in the United States, where 25.8 million people
(8.3% of the population) have diabetes. Impaired wound healing is a major complication
of diabetes. Factors that play a decisive role in diabetes-associated wound healing
disorders comprise augmented inflammatory responses, impaired granulation tissue
formation, reduced growth factors and a disturbed angiogenesis.
Wound angiogenesis is pivotal to wound healing and results from multiple signals acting
on endothelial cells (ECs). VEGF is one of the most potent angiogenic mediators, with
keratinocytes and macrophages being the major producers. As another possible factor
that may affect connective tissue healing, epithelial-mesenchymal transition (EMT) is
recognized as a process that contributes to embryogenesis, tissue remodeling, fibrosis,
and metastatic malignancies. It is an orchestrated series of events during which
epithelial cells lose many of their epithelial specific characteristics and acquire features
typical of mesenchymal cells. Although this concept has been mentioned sporadically in
the literature as an important aspect of wound healing, there is no in vivo evidence that
EMT plays a direct role in oral repair processes.
Forkhead box O1 (FOXO1), which belongs to a large family of forkhead transcription
factors, participates in a wide range of cellular processes, including cell cycle arrest,
DNA repair, apoptosis, oxidative stress resistance, angiogenesis and glucose
metabolism. Recent studies from our lab showed that lineage-specific FOXO1 deletion in
keratinocytes interfered with re-epithelialization in normal skin and mucosal wounds.
Surprisingly, the same deletion of FOXO1 in diabetic wounds had the opposite effect,
significantly improving re-epithelialization. As keratinocytes are a major source of growth
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factors such as VEGF, FOXO1 activity in keratinocytes may affect connective tissue
healing, but this important question has not been previously investigated in vivo.

Based on these findings, my central hypothesis is that FOXO1 deletion in keratinocytes
significantly affects both normal and diabetic gingival connective tissue healing and is
associated with regulation of mediators that stimulate angiogenesis and EMT. The goals
of this study are: 1) to evaluate the effect of lineage specific FOXO1 deletion in
keratinocytes during both normal and diabetic gingival connective tissue wound healing;
2) to determine whether FOXO1 organizes keratinocyte activity to regulate angiogenesis
during both normal and diabetic gingival connective tissue wound healing; 3) to evaluate
the effect of lineage specific FOXO1 deletion in keratinocytes on epithelial-mesenchymal
transition (EMT) during both normal and diabetic gingival connective tissue wound
healing.
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CHAPTER 2
MATERIALS AND METHODS

Animals and induction of diabetes

Animal experiments were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee. Mice with floxed Foxo1 were provided by R.A.
DePinho (MD Anderson Cancer Center, Houston, TX) as previously described (116).
Mice expressing Cre recombinase under the control of keratin 14 promoter (K14-Cre;
strain Tg(KRT14-cre)1Amc/J) were obtained from the Jackson Laboratory. Lineagespecific Foxo1 deletion was obtained by crossing these
mice to generate experimental (K14.Cre+.Foxo1L/L) and
control (K14.Cre-.Foxo1L/L) mice (Fig. 11). Two to five
mice were housed per cage under standard conditions
with a 14-h light/10-h dark cycle. All the experiments
were performed with adult mice 10–20 weeks old. Type
Figure 11. Genotype results
We tested with K14 specific
primer instead of generic Cre
primer.

1 diabetes was induced by multiple low dose i.p.
injections of streptozotocin (50 mg/kg; Sigma-Aldrich) in

10 mM citrate buffer daily for 5 d. Control mice were treated identically with vehicle
alone. The blood glucose levels were monitored after completion of multiple low dose
streptozotocin or citrate buffer injections. Mice were considered to be hyperglycemic
when serum glucose levels were >220 mg/dl. Experiments were performed when mice
had been hyperglycemic for at least 10 days.
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For the EMT study we purchased transgenic mice having a tamoxifen inducible Cremediated recombination system driven by the human keratin 14 (KRT14) promoter
(K14CreER; strain T g (K RT 1 4 c r e /E R )2 0 E fu /J ) from the Jackson Laboratory. This
promoter is strongly active in dividing cells of epidermis and other stratified squamous
epithelia. In order to characterize the recombination properties of a Cre transgenic
mouse line, we crossed K14CreER transgenic mice with ROSA26 Cre reporter mouse
(B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J). To induce Cre activity, we administered
tamoxifen (5 mg per mouse per day) orally to the K14CreER-ROSA26 mice for 5
consecutive days as described (117). Oral wound surgery was performed 1 week after
the last administration (118).

Gingival wounding experiment

Mice

were

anaesthetized

by

i.p.

Rt
Incisors

administration of ketamine (80 mg/kg),
xylazine (5 mg/kg) and acepromazine (1

1st molar
1 mm

2nd molar
3rd molar

mg/kg). Full-thickness wounds were made
in the palatal gingiva near the right first
molar by means of a 1-mm biopsy punch
(Accu-Punch;

Figure 12. Gingival wound making
1 mm full-thickness wound was made in
the palatal gingiva near the right first molar.

Electron

Microscopy

Sciences, USA) as described previously
(119) (Fig. 12). A 1 mm wound size is

commonly used in oral wound studies with mice. Larger oral wounds may jeopardize the
animal’s wellbeing because of difficulty of eating. Wounds were assessed for both 4 and
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7 days post-wounding (n = 7-9 for each group). For The EMT study we examined
wounds after 4, 7 and 14 days (n = 2-4 for each group).

Histology

Specimens were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for
24 h and decalcified in 10% EDTA solution. Wounds were bisected in caudocranial
direction and embedded in paraffin. 4-µm paraffin sections were stained with
hematoxylin and eosin (H&E) and Masson’s trichrome and histomorphometric analysis
was performed with NIS-elements D image analysis software at the center of each
lesion. Masson’s trichrome stain produces red keratin and muscle fibers, blue or green
collagen and bone, light red or pink cytoplasm, and dark brown to black cell nuclei.
Mature collagen fibers take deep blue color and the new collagen fibers stain light blue.
For quantification of newly formed collagen in Masson’s trichrome-stained slides images
were taken with a 20x objective from the middle and/or the two edges of the wound.
Using NIS-elements software (Nikon), the intensity RGB threshold was set for the blue–
green positive color of collagen and the area of positive pixels was counted. For the
EMT study palatal gingival tissues were harvested and embedded in OCT medium
(Sakura Finetek USA, Inc., Torrance, CA, USA), immediately frozen on dry ice, and
sectioned at 10-µm thickness. Samples were stained with DAPI and assessed by
fluorescence microscopy.

Immunohistochemistry in histological sections
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Paraffin-embedded,

formalin-fixed

sample

sections

were

processed

for

immunofluorescence analyses. Antigen retrieval was performed in 10 mM of citric acid,
pH 6.0, at 120°C except for VEGFa, for which Proteinase K was used at room
temperature for 30 minutes. Sections were incubated with primary antibody to FOXO1
(rabbit; Santa Cruz Biotechnology, Inc.), CD31 (rabbit; Abcam), α-SMA (rabbit; Abcam),
VEGFa (rabbit; Abcam) and Ki67 (rat; eBioscience) overnight at 4°C as well as the
appropriate isotype-matched negative control IgG. Biotinylated secondary antibody
(Vector Laboratories) and ABC reagent (Vector Laboratories) were then used. Tyramide
signal amplification (Adipogen) was also used to enhance the chromogenic signal.
Finally, Alexa Fluor 546–conjugated streptavidin (Invitrogen) and/or fluorescein avidin
(Vector Laboratories) and DAPI-containing mounting media were used to visualize the
staining (Sigma-Aldrich). In order to rule out the pericytes, we excluded α-SMA positive
cells if they are morphologically associated with blood vessels. This was assisted by use
of immunofluorescence with antibody to CD31 in adjacent slides to detect blood vessels.
In order to further assess how keratinocytes through FOXO1 regulate connective tissue
healing we analyzed fibroblasts/endothelial cell proliferation with an antibody to Ki67 and
apoptosis with TUNEL assay with/without an antibody to CD31. Fibroblasts were
identified by their typical spindle-shaped appearance. Apoptosis was quantified by
TUNEL assay and samples were incubated at 37°C for an hour with fluorescein-12dUTP (Thermo Fisher Scientific) catalytically incorporated by recombinant terminal
deoxynucleotidyl transferase (Promega). Negative controls were similarly treated with
the omission of rTDT.
Images were taken at 4x, 20x, and 40x magnification with a fluorescence microscope
(ECLIPSE 90i; Nikon) with the same exposure time for experimental and negative
control groups. Image analysis was performed using NIS Elements AR image analysis
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software. The number of immunopositive cells divided by the area or number of DAPIpositive cells was used to measure the percentage of positive cells for each measured
antibody. Mean fluorescence intensity was measured by NIS Elements AR image
analysis software, with a maximum fluorescence intensity set at 3,000 arbitrary units to
obtain results in the linear response range. For the EMT study we washed the samples
with PBS and mounted with DAPI. Images were taken as previously described.

Cell culture and transfection

Human immortalized gingival keratinocytes (HIGK) cells were provided by Jeffrey J.
Mans (University of Florida, Gainesville, FL), immortalized with human papilloma virus
type 16, the E6/E7 gene and maintained in KGM-2 growth medium supplemented with
human

keratinocyte

keratinocytes

were

growth
isolated

supplements
from

the

(Lonza).
neonates

Primary
(0–2d)

mouse
of

epidermal

experimental

(K14.Cre+.Foxo1L/L) and control (K14.Cre-.Foxo1L/L) mice. In brief, mouse skin was
collected and digested with 2.5 U/ml Dispase II (Roche) overnight at 4°C. The dermis
was then separated from the epidermis by digesting with 0.1% trypsin and 0.02% EDTA
in PBS for 15 min at 37°C. Keratinocytes from the epidermis were cultured in KGM-2
growth medium containing antibiotics. All cell cultures were maintained in a 5% CO2
humidified incubator at 37°C. Keratinocytes were passaged in KGM-2 growth media with
supplements including standard insulin (8.6 x 10-7 M). For assays, cells were transferred
to KGM-2 media with supplements except the insulin. ON-TARGETplus SMARTpool
siRNAs against human FOXO1 and control siRNA (ON-TARGETplus Non-targeting
Control Pool) were obtained from GE Healthcare and transfection was performed using
GenMute siRNA Transfection Reagent (SignaGen Laboratories). In most transfection
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experiments, cells were incubated for 6 h with siRNA and transfection reagent 2 d before
assay. Cells were then rinsed and transferred back to the indicated culture media for the
remaining incubation period.

Immunofluorescence analysis in vitro

Primary keratinocytes isolated from K14.Cre+.Foxo1L/L and K14.Cre-.Foxo1L/L mice and
HIGK cells were grown on 96-well plates. HIGK cells were transfected with FOXO1 or
scrambled siRNA. After 24 hour incubation in KBM-2 media with/without supplements
except insulin, both primary keratinocytes and HIGK cells were fixed with 10% formalin,
permeabilized with 0.5% Triton X-100 and incubated overnight at 4oC with primary
antibodies to FOXO1 (rabbit; Santa Cruz Biotechnology, Inc.), VEGFa (rabbit; Santa
Cruz Biotechnology Inc.) or negative control IgG. Primary antibody was localized with
biotinylated secondary antibody and visualized with streptavidin-conjugated Alexa Fluor
546. Avidin-biotin peroxidase enzyme complex (Vector Laboratories) and tyramide signal
amplification (Adipogen, San Diego, CA, USA) were used to enhance the fluorescent
signal. Nuclei were stained with DAPI. Images were captured with a fluorescence
microscope (Nikon) and the mean fluorescence intensity (MFI) was determined using
NIS Elements AR software (Nikon).

Luciferase reporter assay

Transient transfection with luciferase reporter constructs was performed using
Lipofectamine3000 (Invitrogen) in 48-well plates. In brief, HIGK cells were incubated in
culture media with/without insulin for 5 d with 5 mM d-glucose. Cells were cotransfected
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with VEGFa luciferase reporter (provided by Dr. Keping Xie, University of Texas M. D.
Anderson Cancer Center, Houston, TX) (120) together with pRL-TK luciferase control
vector, FOXO1-AAA plasmid that is constitutively transported to the nucleus, pcDNA3.1
control plasmid, scrambled or FOXO1 siRNA. 2 d after transfection, cells were lysed,
and Firefly and Renilla luciferase activities were measured using Dual Luciferase
Reporter Assay kit (Promega) according to the manufacturer’s instructions. Firefly
luciferase activities were divided by Renilla activities to normalize for transfection
efficiency. Experiments were performed three times with similar results. In some
experiments, primary murine keratinocytes from K14.Cre-.FOXO1L/L mice in low (5 mM
d-glucose) glucose medium were cotransfected with VEGFa luciferase reporter together
with pRL-TK luciferase control vector, FOXO1, FOXO1-AAA plasmid and pcDNA3.1
control plasmid. 2 days after transfection, cells were lysed and tested with the Dual
Luciferase Reporter Assay (Promega).

Microarray analysis

Normal human epidermal keratinocytes (NHEK) cells were incubated in low (5 mM dglucose) or high (25 mM d-glucose) glucose medium for 5 days and transfected with
FOXO1 or scrambled siRNA. Total RNA was then isolated using an RNeasy kit
(QIAGEN). RNA profiling was performed using a GeneChIP Human Gene 1.0 ST array
(Affymetrix). The identification of genes that were up- or down-regulated by high glucose
and FOXO1 knockdown was defined as those that were both up-regulated (>1.3-fold) by
high glucose and down-regulated (<0.7-fold) by FOXO1 siRNA with P < 0.05, both when
compared with the matched control group.
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Statistics

Statistical analysis between Cre+ and Cre- groups was performed using 2-tailed
Student’s t test. In experiments with multiple time points or treatments, differences
between the wild type and experimental groups were determined by ANOVA with
Scheffe's post-hoc test. Results were expressed as the mean ± SEM. P< 0.05 was
considered statistically significant.
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CHAPTER 3
RESULTS

3.1 To evaluate the effect of lineage specific FOXO1 deletion in keratinocytes
during both normal and diabetic gingival connective tissue wound healing

3.1.1 Keratinocyte-specific FOXO1 deletion impairs connective tissue healing in
normoglycemic
mice while
showing no significant difference in diabetic mice
FOXO1
DAY4
DIABETIC
(NEW)
K14.Cre-.FOXO1L/L

K14.Cre+.FOXO1L/L

1-mm

full-thickness

FOXO1

wounds were created in
the palatal gingiva near
the right first molar in
experimental transgenic
FOXO1/ DAPI

mice (K14.Cre+.Foxo1L/L)
with keratinocyte-specific
deletion of Foxo1 driven
by

Figure 13. FOXO1 Immunofluorescence
demonstrating lineage-specific Foxo1 deletion in keratinocytes

keratin-14

recombinase
littermate

Cre
and
control

(K14.Cre-.Foxo1L/L) mice without Foxo1 deletion. We confirmed that Foxo1 expression
was decreased by Cre recombinase in the epithelium compared with matched control
mice, consistent with our previous results (113). In contrast, there was little difference
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observed

in

the

connective

tissue, demonstrating

lineage-specific

deletion

in

keratinocytes (Fig. 13).
Deletion of Foxo1 in keratinocytes of nondiabetic mice delayed connective tissue healing
(day 4, Fig. 14 A-D). The gap between the edges of connective tissue was increased by
keratinocyte-specific FOXO1 deletion in both day 4 and 7 nondiabetic wounds (P<0.05).
Even though both normoglycemic experimental and control mice showed the complete
re-epithelialization on day 7, there was the incomplete bridging of the wound by
connective tissue in experimental K14.Cre+.Foxo1L/L mice (Fig. 14 E and F, H & E). Both
granulation tissue formation and collagen production in the normoglycemic wounds of
experimental K14.Cre+.Foxo1L/L mice was reduced, but diabetic mice showed the similar
results between experimental and control mice on both day 4 and day 7 wounds (Fig. 15
A-D, Masson’s trichrome stain). Thus, keratinocyte-specific Foxo1 deletion in
normoglycemic mice has a pronounced effect on healing of connective tissue.

Figure 14. Keratinocyte-specific deletion of FOXO1 impairs gingival connective tissue
healing responses in normoglycemic wounds. (A-C) Quantification of normoglycemic wound
healing in H&E stained sections (day 4) including (A) wound gap, (B) area and (C) length. (D)
-

Hematoxylin and eosin (H & E) staining of both normal and diabetic K14.Cre .Foxo1
+

L/L

-

L/L

K14.Cre .Foxo1
K14.Cre .Foxo1

L/L

and

mice wound biopsies on day 4 after wounding (10x). (E) Normoglycemic
+

and K14.Cre .Foxo1

L/L

mice wound biopsies on day 7. Red circles demonstrate

the difference of connective tissue healing between the experimental and control mice. There was
+

the incomplete bridging of the wound by connective tissue in experimental K14.Cre .Foxo1

L/L

mice (10x). (F) Connective tissue gap on day 7. EPI, epithelium; CT, connective tissue; B, bone.
-

Each in vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre group; #,
P<0.05 versus matched normoglycemic control group.
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Figure 14
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Figure 15. Keratinocyte-specific deletion of FOXO1 decreases collagen production in

A.#20X#
100#um#

normoglycemic wounds. (A) Old collagen fibers take deep blue color and the new collagen
fibers stain light blue, representing mature or early collagen (20x). (B) Representative images of
Masson's trichrome staining (10x). (C and D) Newly formed collagen on both day 4 and 7 was
measured in Masson's trichrome stained sections. Each in vivo value is the mean ± SEM for n=7-

9 mice per group. *, P<0.05 versus Cre group; #, P<0.05 versus matched normoglycemic control
group.
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3.1.2 Keratinocyte-specific FOXO1 deletion in normal wounds results in decreased
fibroblast proliferation and increased apoptosis in vivo
	
  
The effect of keratinocyte-specific Foxo1 deletion on fibroblast numbers was assessed in
vivo. Fibroblast density in connective tissue was reduced by 56% in normoglycemic
wounds (day 4, P<0.05), but was similar with or without keratinocyte-specific FOXO1
deletion in diabetic wounds (Fig. 16 A-C). Myofibroblasts are crucial for the wound
contraction and maturation. The number of myofibroblasts was reduced 57% by FOXO1
deletion in epithelium in normal wounds (P<0.05) but increased by 82% (Day 4) and
28% (Day 7) in diabetic wounds (P<0.05) (Fig. 17 A-D). The differentiation of fibroblasts
to myofibroblasts is a key event in connective tissue wound healing (121). When tissues
are injured, fibroblasts are activated and differentiate into myofibroblasts, which contract
and participate in healing by reducing the size of wound and secreting extracellular
matrix (ECM) proteins. We next investigated the effect of keratinocyte-specific Foxo1
deletion on fibroblast proliferation and apoptosis in vivo. The percentage of proliferating
fibroblasts was measured by the number of Ki67–positive fibroblasts divided by total
fibroblast number. Ki-67 is used as a marker for determining the growth fraction of a
given population of cells. Ki-67 is present during all active phases of the cell cycle (G1,
S, G2, and mitosis), but is absent from resting cells (G0). During interphase, the Ki-67
antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of
the protein is relocated to the surface of the chromosomes. The percentage of
proliferating fibroblasts was reduced by 68% (day 4 normal) in K14.Cre+.Foxo1L/L mice
compared to littermate control mice (P<0.05), indicating impaired fibroblast proliferation
with epithelial-specific FOXO1 deletion (Fig. 18 A and B). In diabetic wounds the
percentage of proliferating fibroblasts was similar on day 4, but showed a 2.7 fold 	
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Figure 16. Fibroblast Density
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Figure 16. Keratinocyte-specific deletion of FOXO1 decreases fibroblast density in
normoglycemic wounds. (A) Representative images of Hematoxylin and eosin (H & E) staining
-

of K14.Cre .Foxo1

L/L

+

and K14.Cre .Foxo1

L/L

mice wound biopsies on day 4 after wounding (40x).

Fibroblasts were identified by their typical spindle-shaped appearance. (B and C) Fibroblast
density in newly formed connective tissue was measured in H & E stained histologic sections.
-

Each in vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre group; #,
P<0.05 versus matched normoglycemic control group.
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Figure 17 a-SMA immunofluorescence ( A,B D4)
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Figure

17.

Keratinocyte-specific

deletion

of

FOXO1

decreases

the

number

of

myofibroblasts in normoglycemic wounds but increases in diabetic wounds. (A and B)
Representative images of α-SMA immunofluorescence (40x, day 4, normoglycemic and diabetic
mice) (C and D) α-SMA immunofluorescence analyses of myofibroblasts in newly formed
connective tissue. Each in vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05
-

versus Cre group; #, P<0.05 versus matched normoglycemic control group.
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increase in K14.Cre+.Foxo1L/L mice on day 7 (P<0.05). The percentage of apoptotic
fibroblasts increased by 3-fold in Foxo1-deficient normoglycemic wounds compared with
control mice (P<0.05) on day 4 but decreased by 60% in FOXO1-deficient diabetic
wounds on day 7 (P<0.05) (Fig. 18 C and D). In addition, we observed a 53% decrease
in keratinocyte proliferation in the normoglycemic wound epithelium of Foxo1-deleted
mice (day 4, P<0.05) (Fig. 18 E and F).

Figure 18. Keratinocyte-specific FOXO1 deletion in normal wounds reduces fibroblast
proliferation but enhances apoptosis. (A and B) Ki67 immunofluorescence analyses of
proliferating fibroblasts in connective tissue. Fibroblasts were identified by their typical spindleshaped appearance. (C and D) Apoptotic fibroblasts were measured by TUNEL staining. (E and
F) Quantification of Ki67 immunopositive keratinocytes. Each in vivo value is the mean ± SEM for
-

n=7-9 mice per group. *, P<0.05 versus Cre group; #, P<0.05 versus matched normoglycemic
control group.
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3.2 To determine whether FOXO1 organizes keratinocyte activity to regulate
angiogenesis during both normal and diabetic gingival wound healing.

3.2.1

Keratinocyte-specific

FOXO1

deletion

impairs

neovascularization

in

normoglycemic mice while showing no significant difference in diabetic mice

Angiogenesis in the wound granulation tissue was compared between experimental
(K14.Cre+.Foxo1L/L) and control (K14.Cre-.Foxo1L/L) mice based on the expression of the
endothelial cell marker CD31 (Fig. 19 A and B). Vascular density was calculated as the
number of CD31 immunopositive blood vessels/mm2. Foxo1 ablation in keratinocytes of
normoglycemic mice decreased vascular density in connective tissue by 52% (day 4)
and 44% (day 7) compared with control littermates (P < 0.05) (Fig.19 C and D). In
contrast, keratinocyte-specific Foxo1 ablation in diabetic mice did not affect vascular
density in experimental compared to matched control mice (P > 0.05).
To investigate mechanisms through which FOXO1 deletion in epithelium affected
angiogenesis during wound healing, endothelial cell proliferation and apotosis were
assessed in vivo. Foxo1 deletion in normoglycemic mice caused a significant 40% (day
4) and 49% (day 7) reduction in the percentage of both Ki67 and CD31–positive
proliferating EC in wounds (P < 0.05; Fig. 19 E and F). In contrast, Foxo1 deletion in
keratinocytes of diabetic mice did not show the significantly different results. The
percentage of apoptotic EC is very low in our study.
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Figure 19. Keratinocyte-specific FOXO1 deletion in normal wounds reduces vascular
density and endothelial cell proliferation. (A and B) CD31 immunofluorescence analyses in
newly formed connective tissue (40x, day 4, normoglycemic and diabetic mice). (C and D)
Vascualr density in newly formed connective tissue. (E and F) Quantification of CD31 and Ki67
double immunopositive cells for analyses of proliferating endothelial cells. Each in vivo value is
-

the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre group; #, P<0.05 versus
matched normoglycemic control group.

	
  
3.2.2 The effect of keratinocyte-specific FOXO1 deletion on angiogenesis is
mediated by VEGF-A

Transfection of HIGK cells with FOXO1 siRNA significantly reduced VEGFa protein
levels by 57% in standard glucose media (P<0.05; Fig. 20 A-C). Keratinocyte-specific
FOXO1 deletion in vivo also significantly reduced VEGF-A protein levels by 53% (day 4,
p<0.05) and 42% (day 7, p<0.1) in wounded epithelium from normoglycemic mice but
had little effect on VEGF-A levels in diabetic mice (P>0.05) (Fig. 21 A-D). Surprisingly in
normal wounds VEGF-A expression in the connective tissue was reduced by 58% (day
4, p<0.05) and 52% (day 7, p<0.05) when FOXO1 was deleted in epithelium, indicating
that keratinocytes play an important role in VEGF-A expression in connective tissue. In
diabetic wounds VEGF-A expression in both epithelium and connective tissue were
similar between experimental (K14.Cre+.Foxo1L/L) and control (K14.Cre-.Foxo1L/L) mice
on day 4 but there was a small but significant 1.7 fold increase of VEGF-A expression in
connective tissue on day 7 (p<0.05). This is consistent with our vascular density results.
To determine whether FOXO1 can regulate VEGF-A transcriptional activity, we
examined the luciferase activity of the VEGF-A reporter in HIGK and primary mouse
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epidermal keratinocytes. The luciferase reporter analysis revealed that overexpression
of constitutively active FOXO1 (FOXO1AAA) results in a 2.1-fold increase in VEGF-A
transcriptional activity in HIGK cells and a 3.3-fold increase in primary mouse epidermal
keratinocytes, whereas FOXO1 silencing produced a 20-43% decrease in VEGF-A
promoter activity in HIGK cells (P < 0.05; Fig. 22 A-C). These results indicate that
FOXO1 transactivates VEGF-A promoter activity and suggests that VEGF-A may be a
downstream target of FOXO1.
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Figure 15 VEGF-A Immunofluorescence (HIGK)
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Figure 20. FOXO1 deletion in keratinocytes reduces VEGF expression in normal glucose
media. (A) Representative images of VEGF-A immunofluorescence in human immortalized
gingival keratinocytes (HIGK). (B) FOXO1 mean fluorescence intensity analysis. (C) VEGF-A
mean fluorescence intensity analysis. In vitro values represent the mean ± SEM of three
independent experiments. *P<0.05
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Figure 16 VEGF-A immunofluorescence (FINAL)
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Figure 21. FOXO1 deletion in keratinocytes in normoglycemic wounds reduces VEGF
expression in vivo. VEGF-A immunofluorescence on normoglycemic (A) and diabetic wounds
(B) (day 4). VEGF-A mean fluorescence intensity analysis on day 4 (C) and day 7 (D). Each in
-

vivo value is the mean ± SEM for n=7-9 mice per group. *, P<0.05 versus Cre group; +, P<0.1
-

versus Cre group; #, P<0.05 versus matched normoglycemic control group.
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Figure 17 VEGF-A Luciferase Reporter Assay
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Figure 22. FOXO1 transactivates VEGF expression in normal glucose media. (A-C) VEGF-A
luciferase reporter gene analyses. FOXO1 overexpression in HIGK cells (A) and primary mouse
epidermal keratinocytes (PMEK) (B). FOXO1 silencing in HIGK cells (C). Data show mean ± SEM
of at least three independent experiments. *P < 0.05
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3.3 To evaluate the effect of lineage specific FOXO1 deletion in keratinocytes on
epithelial-mesenchymal transition (EMT) during both normal and diabetic gingival
connective tissue wound healing.

We examined K14CreER-ROSA26 mice in which keratinocytes were genetically altered
to permanently express TdTomato with tamoxifen administration, allowing us to map the
fate of these cells and definitively test in vivo whether EMT occurs during wound healing.
TdTomato was strongly expressed following Cre-mediated recombination with tamoxifen
administration. But, we did not find the reporter activity in the connective tissue indicating
that there was no transition to typical fibroblasts or myofibroblasts with initial samples

EMT$Study*CUT$

EMT$Study*CUT$

(n=2-4 per each group) (Fig. 23 A-E).

Day'7'

Day'14'

TdTomato'

Day'4'
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TdTomato/'DAPI'

TdTomato'

Nega0ve'Control'

Figure 23 DAPI stain of oral wounds of K14CreER-ROSA26 mice. (left to right)
Negative control, day 4 experimental, day 7 experimental and day 14 experimental
wounds. (20x)

51	
  
	
  
	
  

CHAPTER 4
DISCUSSION

VEGF-A is a key molecule that orchestrates the formation and function of vascular
networks (122). It functions as an endothelial cell mitogen (123, 124), chemotactic agent
(125), and inducer of vascular permeability (126). Unlike other angiogenic growth factors
such as basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGFβ), VEGF-A affects multiple components of the wound-healing cascade including
angiogenesis, re-epithelialization and collagen deposition. The endothelium of the
microvasculature exhibits several important responses to extracellular VEGF-A including
increased endothelial proliferation and increased permeability, exerted through a change
in endothelial cell structure and function (127, 128). Several lines of evidence indicate
that FOXO1 deletion in keratinocytes in vivo led to deficient angiogenesis and
substantially reduced the expression of VEGF-A during normal wound healing. In vitro
HIGK cells with FOXO1 knockdown by siRNA substantially reduced VEGF-A expression
and decreased VEGF-A promoter activity, and Cre recombinase deletion of Foxo1 in
primary

mouse

keratinocytes

reduced

VEGF-A

protein

levels.

Conversely,

overexpression of constitutively active FOXO1 in both HIGK and primary murine
keratinocytes significantly increased VEGF-A promoter activity in luciferase reporter
assays. These results suggest that the avascular epidermis has the capacity to regulate
angiogenesis by a paracrine mechanism involving the secretion of VEGF-A and FOXO1
is needed for adequate VEGF-A expression.
Interestingly we found that FOXO1 deletion in keratinocytes affected the VEGF-A
expression in both epithelium and connective tissue. As a possible explanation one of
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the major cellular components of wound granulation tissue relevant to healing and
angiogenesis is macrophages (23, 24, 129). Macrophages in the wound tissue supply
pro-inflammatory chemoattractants to recruit and activate additional macrophages,
which participate in wound repair by secreting cytokines that induce angiogenesis, such
as VEGF and TGF-β. Macrophages can also increase vascular permeability by releasing
vasoactive substances such as vascular permeability factor (130), substance P (131),
platelet activating factor and prostaglandins (132). Macrophage depletion during wound
healing in mice results in decreased wound levels of TGF-β1 (27), suggesting that
macrophages represent a major cellular source of TGF-β1 during normal wound healing
(133). Evidence obtained in macrophage-deficient mice confirmed the essentiality of
macrophages to the neovascularization of wounds (25, 27, 134, 135). Goren et al.
showed that the altered expression patterns of vascular endothelial growth factor on
macrophage reduction were associated with a disturbed neovascularization at the
wound site (26). Leibovich et al. demonstrated that mice with non-functioning
macrophages display retarded wound repair (134). This retarded wound repair includes
delayed re-epithelialization, delayed neovascularization and aberrant granulation tissue
formation (27, 135). Mirza et al. showed that macrophage depletion resulted in delayed
re-epithelialization, decreased collagen deposition, impaired angiogenesis, and reduced
cell proliferation associated with increased production of tumor necrosis factor (TNF)-α
and decreased production of TGF-β1 and vascular endothelial growth factor (VEGF)
(27). Also TGF-β1 is known for a chemoattractant for macrophages (136) and our
previous study proved that FOXO1 regulates TGF-β1 in keratinocytes (110). However,
most of studies still demonstrate that keratinocytes are the main producer of VEGF-A
during wound healing (4, 9, 65). Brown et al. revealed that greatly increased amounts of
vascular permeability factor (VPF) mRNA were expressed by keratinocytes, initially
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those at the wound edge and at later intervals, keratinocytes that migrated to cover the
wound surfaces; occasional mononuclear cells also expressed VPF mRNA (4). Rossiter
et al. performed wound-healing studies in mice with VEGF-A-deficient keratinocytes and
showed that the wounds contained fewer blood vessels beneath the epidermis and
healed more slowly (65).
The contribution of VEGF-A to overall wound closure and epidermal repair has been
examined extensively in animal studies (1). VEGF-A, which is normally expressed at low
levels by epidermal keratinocytes, is up-regulated in these cells in injured skin (4).
Studies in human wounds and animal models have indicated that VEGF-A is produced
by keratinocytes early and later stages in the wound-healing process (64, 137).
Activated fibroblasts, mast cells, and macrophages also express VEGF-A in injured skin
(4, 138, 139). Traditionally, VEGF-A produced by epidermal keratinocytes was thought
to act in a paracrine manner, stimulating endothelial cells in blood vessels within the
underlying dermis (1). The expression of the flt-1 receptor for VEGF-A is up-regulated in
the sprouting blood vessels at the wound edge and in endothelial cells of the granulation
tissue (54). However VEGF-A has been shown to stimulate keratinocyte migration and
collagen production via fibroblasts (53). Functional VEGFRs have been recently
identified on keratinocytes (72-75), which suggests the possibility of autocrine VEGF-A
signaling in keratinocytes as well as direct effects of VEGF-A derived from other cellular
sources on keratinocytes. Several studies have also shown that VEGF-A enhances
macrophage recruitment in vivo (140-143). Hong et al. demonstrated an increase in the
density of macrophages has been observed in wounds created in transgenic mice that
overexpress VEGF-A in the epidermis, suggesting that VEGF-A plays a role in recruiting
macrophages to damaged skin (81). Reducing VEGF-A activity by treating with
neutralizing antibodies or small molecule inhibitors of VEGF-A signaling or conditional
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genetic deletion of VEGF-A lead to delayed healing (65, 72, 144, 145). Additionally,
topical treatment with neutralizing antibodies to VEGFR-1 results in reduced reepithelialization rates (72). Both keratinocyte-derived and myeloid cell–derived VEGF-A
have been shown to affect some components of the repair process (65, 137, 144). For
example, delayed wound closure, reduced vessel density, and decreased granulation
tissue formation have been reported in mice lacking VEGF-A in myeloid cells (137, 144),
and delayed wound closure and reduced vessel density have been reported in mice
lacking VEGF-A in keratinocytes (65). Direct and indirect evidences implicate VEGF-A
as a significant factor in wound healing immediately after injury.
Angiogenesis, the sprouting of new capillaries from the preexistent blood vessels, is of
central importance in many biological processes, including embryonic vascular
development and differentiation, wound healing, and organ regeneration (115, 146, 147).
In addition, angiogenesis plays a major role in pathological conditions such as diabetic
retinopathy, rheumatoid arthritis, psoriasis, cardiovascular diseases, tumor growth, and
metastasis (148, 149). During angiogenesis, endothelial cells migrate, proliferate,
organize into tube-like structures, and play an active role in tissue remodeling. In our
study FOXO1 deletion in keratinocytes reduced endothelial cells proliferation in vivo.
Endothelial cell apoptosis in vivo can be evaluated by one or more of several techniques,
including immunofluorescence staining for endothelial specific markers, detection of
DNA strand breaks by terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL), assay for caspase activation and measurement of phosphatidyl serine
exposure by annexin V binding (150-152). Morphologic changes characteristic of
apoptosis were also identified: cell shrinkage, nuclear and cytoplasmic condensation,
and cellular budding into "apoptotic bodies”. In our study we could find TUNEL positive
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cells but observe very little endothelial cell apoptosis. Generally apoptotic cell death and
in particular endothelial cell apoptosis may be difficult to observe in vivo as apoptotic
cells are rapidly phagocytosed and their digestion can be completed within 60 min (153,
154). Notably, endothelial cells can engulf apoptotic cells or apoptotic bodies (155, 156).
Moreover, apoptotic endothelial cells may detach from the vessel wall into the circulation.
Another possible reason is the time points for endothelial cell apoptosis. At the end of
the proliferative phase fibroblasts start to undergo apoptosis. Endothelial cells and
remaining fibroblasts disappear upon the completion of wound maturation (11).
Desmouliere et al. examined apoptotic patterns in cells in open wounds created in rats
(157). They found that apoptosis in myofibroblasts began on day 12, peaked at 20 d and
resolved by 60 d suggesting that myofibroblast apoptosis begins about the same time as
wound closure. Apoptosis patterns in the cells of the neovasculature similarly started at
around 12 d and had maximal expression of apoptosis between 16 and 25 d. The
parallel apoptosis patterns of fibroblasts and endothelial cells suggest that there is a
coordinated decrease in cellularity with wound maturation that may involve cell to cell
communication. In our study we used both day 4 and 7, when wound closure starts but it
may be early for the endothelial cell apoptosis.
In our study we found that FOXO1 deletion in epithelium led to impaired connective
tissue healing that included decreased formation of new connective tissue in normal
mice. Fibroblast numbers and proliferation were both reduced when FOXO1 was deleted
in keratinocytes consistent with impaired production of extracellular matrix. In addition
keratinocyte-specific FOXO1 deletion led to reduced myofibroblast numbers. Our results
agree with the previous papers (110). As a possible mechanism TGF-β1 and connective
tissue growth factor (CTGF) are the key regulators of connective tissue healing
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prompting the expression of ECM proteins such as collagen and initiating granulation
tissue formation (158). TGF-β stimulates the expression of CTGF, which is thought to be
responsible for many of the pro-fibrotic properties of TGF-β, particularly in the promotion
of fibroblast proliferation and ECM production (159, 160). CTGF plays a physiological
role in early wound healing (161). Previous studies in our lab found that TGF-β1 and
CTGF expression in both epithelium and connective tissue were decreased by
keratinocyte-specific deletion of FOXO1 during wound repair (submitted). Interestingly,
they found that the same deletion of FOXO1 in diabetic wounds had the opposite effect,
significantly improving the healing response (111, 113). However in our study we found
that diabetic wound healing was impaired, compared with normal mice group but there
was no significant difference between diabetic experimental and control groups. A
possible explanation for those similar results is a relatively significant commensal flora in
oral cavity that might mask the effect of FOXO1 deletion in keratinocytes. The bacteria of
the oral cavity have the potential to alter the wound healing process by interacting with
keratinocytes (162). Treatment with antibiotics may significantly diminish the persistent
inflammatory infiltrate and improve healing in the diabetic mice (163).
Although EMT has been mentioned sporadically in the literature as an important aspect
of wound healing, it is still unknown whether EMT occurs during cutaneous wound
healing (164, 165). EMT was originally described as an important cellular programming
that orchestrates formation of mesoderm during gastrulation (83, 166). In last decade
accumulated evidence has uncovered EMT in many chronic diseases such as cancer
progression and fibrotic diseases. Generally the purpose of EMT is believed to mobilize
epithelial cells into motility or invasion through loss of cell-adhesion and polarity and
simultaneous gain of mesenchymal phenotype. TGF-β is the key cytokine involved in
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many elements of wound healing, including the induction of EMT via many pathways.
Previous studies in our lab found that FOXO1 regulates TGF-β, which is one of the
predominant factors that stimulate EMT, in keratinocytes during wound healing.
Therefore we assumed that EMT occurred and it could be regulated by FOXO1.
However, we did not observe trans-differentiation of keratinocytes into typical fibroblasts
or myofibroblasts with lineage tracing in transgenic mice.
In summary, in this study we found that keratinocyte-specific deletion of FOXO1
interfered with normal gingival connective tissue healing by decreasing granulation
tissue formation and angiogenesis, which were mediated by VEGF-A. In particular this is
the first evidence that avascular epithelium regulates angiogenesis involving the VEGFA secretion mediated by FOXO1.
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